



IFW

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10595495
Filing Date	2006-04-24
First Named Inventor	Mermod et al.
Art Unit	
Examiner Name	
Attorney Docket Number	3024-119

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20040077842	A1	2004-04-22	Himawan	
	2	20040088764	A1	2004-05-06	Gleba et al.	
	3	20040103454	A1	2004-05-27	Conkling et al.	
	4	20040115776	A1	2004-06-17	Simesen et al.	
	5	20040126883	A1	2004-07-01	Liu	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10595495
Filing Date	2006-04-24
First Named Inventor	Mermod et al.
Art Unit	
Examiner Name	
Attorney Docket Number	3024-119

	6	20040216189	A1	2004-10-28	Houmard et al.	
	7	20040221330	A1	2004-11-04	Klimyuk et al.	
	8	20040242512	A1	2004-12-02	Misawa et al.	
	9	20050022262	A1	2005-01-27	Vance	
	10	20050034187	A1	2005-02-10	Golovko et al.	
	11	20050050581	A1	2005-03-24	Ivanova et al.	
	12	20050129669	A1	2005-06-16	Treco et al.	
	13	20050130267	A1	2005-06-16	Wolffe et al.	
	14	20030087342		2003-05-08	Mermod et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
-------------------	---------	--------------------------------------	---------------------------	------------------------	------------------	---	--	----------------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10595495
Filing Date	2006-04-24
First Named Inventor	Mermod et al.
Art Unit	
Examiner Name	
Attorney Docket Number	3024-119

1								<input type="checkbox"/>
---	--	--	--	--	--	--	--	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	MANJU AGARWAL, ET AL., Scaffold Attachment Region-Mediated Enhancement of Retroviral Vector Expression in Primary T Cells, Journal of Virology, May 1998, pp. 3720-3728, Vol. 72, No. 5, American Society for Microbiology, US	<input type="checkbox"/>
	2	GEORGE C. ALLEN, ET AL., High-Level Transgene Expression in Plant Cells: Effects of a Strong Scaffold Attachment Region from Tobacco, The Plant Cell, May 1996, pp. 899-913, Vol. 8, American Society of Plant Physiologists, US	<input type="checkbox"/>
	3	ADAM C. BELL and GARY FELSENFELD, Stopped at the border: boundries and insulators, Current Opinion in Genetics & Development, 1999, p. 191-198, Vol. 9, Elsevier Science Ltd., US	<input type="checkbox"/>
	4	XIN BI and JAMES R. BROACH, UASrpg can function as a heterochromatin boundary element in yeast, Genes & Development, 1999, pp. 1089-1101, Vol. 13, Cold Spring Harbor Laboratory Press, US	<input type="checkbox"/>
	5	JURGEN BODE, ET AL., Transcriptional Augmentation: Modulation of Gene Expression by Scaffold/Matrix-Attached Regions (S/MAR Elements), Critical Reviews TM in Eukaryotic Gene Expression, 2000, pp. 73-90, Vol. 10(1), Begell House, Inc., US	<input type="checkbox"/>
	6	ELIETTE BONNEFOY, ET AL., Specific Binding of High-Mobility-Group I (HMGI) Protein and Histone H1 to the Upstream AT-Rich Region of the Murine Beta Interferon Promoter: HMGI Protein Acts as a Potential Antirepressor of the Promoter, Molecular and Cellular Biology, April 1999, pp. 2803-2816, Vol. 19, No. 4, American Society for Microbiology, US	<input type="checkbox"/>
	7	OTMANE BOUSSIF, ET AL., A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine, Biochemistry, August 1995, pp. 7297-7301, Vol. 92, Proc. Natl. Acad. Sci. USA, US	<input type="checkbox"/>
	8	JOAQUIN CASTILLA, ET AL., Engineering passive immunity in transgenic mice secreting virus-neutralizing antibodies in milk, Nature Biotechnology, April 1998, pp. 349-354, Vol. 16, Nature Publishing Group, US	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10595495
Filing Date		2006-04-24
First Named Inventor	Mermod et al.	
Art Unit		
Examiner Name		
Attorney Docket Number		3024-119

9	J. PATRICK CONDREAY, ET AL., Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector, Cell Biology, January 1999, pp. 127-132, Vol. 96, Proc. Natl. Acad. Sci. USA, US	<input type="checkbox"/>
10	GEORGE W. COX, ET AL., Molecular Cloning and Characterization of a Novel MouseMacrophage Gene That Encodes a Nuclear Protein ComprisingPolyglutamine Repeats and Interspersing Histidines, The Journal of Biological Chemistry, October 11, 1996, pp. 25515-25523, Vol. 271, No. 41, The American Society for Biochemistry and Molecular Biology, US	<input type="checkbox"/>
11	OLIVIER CUVIER, ET AL., Identification of a Class of Chromatin Boundary Elements, MOLECULAR AND CELLULAR BIOLOGY, December 1998, pp. 7478-7486, Vol. 18, No. 12, American Society for Microbiology, US	<input type="checkbox"/>
12	DATABASE EMBL [Online] 11 February 1995 (1995-02-11), "G.gallus lysozyme gene promoter" X84223 retrieved from EBI accession no. EM_VRT:X84223 Database accession no. X84223	<input type="checkbox"/> +
13	DATABASE EMBL [Online] 16 July 1990 (1990-07-16), "Chicken Lysozyme gene intrinsically curved segment of DNA" X52989 retrieved from EBI accession no. EM_VRT:X52989 Database accession no. X52989	<input type="checkbox"/> +
14	DATABASE EMBL [Online] 17 May 2000 (2000-05-17), "Cloning vector pMAR luciferase reporter vector containing MAR insulator sequence". AJ277960 retrieved from EBI accession no. EM_SYN:AJ277960 Database accession no. AJ277960	<input type="checkbox"/> +
15	DATABASE EMBL [Online] 14 June 1996 (1996-06-14), "G.gallus lysozyme gene 5' matrix attachment region (MAR) subfragment B-1-H1 X98408 retrieved from EBI accession no. EM_VRT:X98408 Database accession no. X98408	<input type="checkbox"/> +
16	DATABASE EMBL [Online] 4 January 2002 (2002-01-04), "Human DNA sequence from clone RP4-743D20 on chromosome 1 Contains novel gene and a CpG island." XP002322943 retrieved from EBI accession no. EM_HUM:AL663105	<input type="checkbox"/> +
17	MATTHIAS FRISCH, ET AL., In Silico Prediction of Scaffold/Matrix Attachment Regions in Large Genomic Sequences, Genome Research, 2001, pp. 349-354, Vol. 12, Cold Harbor Laboratory Press, US	<input type="checkbox"/>
18	FRANK GROSVELD, Activation by locus control regions?, Current Opinion in Genetics & Development, 1999, pp. 152-157, Vol. 9, Elsevier Science Ltd., US	<input type="checkbox"/>
19	CRAIG HART and ULRICH LAEMMLI, Facilitation of chromatin dynamics by SARs, Current Opinion in Genetics & Development, 1998, pp. 519-525, Vol. 8, Current Biology Limited, US	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10595495
Filing Date		2006-04-24
First Named Inventor	Mermod et al.	
Art Unit		
Examiner Name		
Attorney Docket Number	3024-119	

20	THOMAS JENUWEIN, ET AL., Extension of chromatin accessibility by nuclear matrix attachment regions, Nature, January 16, 1997, pp. 269-272, Vol. 385, Nature Publishing Group, US	<input type="checkbox"/>
21	MARTIN JORDAN, ET AL., Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation, Nucleic Acids Research, 1996, pp. 596-601, Vol. 24, No. 4, Oxford University Press, UK	<input type="checkbox"/>
22	MICHAEL KALOS and R. E. K. FOURNIER, Molecular and Cellular Biology, January 1995, pp. 198-207, Vol. 15, No. 1, American Society for Microbiology, US	<input type="checkbox"/>
23	RANDAL KAUFMAN and PHILLIP SHARP, Amplification and Expression of Sequences Cotransfected with a Modular Dihydrofolate Reductase Complementary DNA Gene, Journal of Molecular Biology, 1982, pp. 601-621, Vol. 159, Academic Press Inc. (London) Ltd., UK	<input type="checkbox"/>
24	DAGMAR KLEHR, ET AL., Scaffold-Attached Regions from the Human Interferon β 3 Domain Can Be Used To Enhance the Stable Expression of Genes under the Control of Various Promoters, Biochemistry, 1991, pp. 1264-1270, Vol. 30, American Chemical Society, US	<input type="checkbox"/>
25	TED H.J. KWAKS, ET AL., Identification of anti-repressor elements that confer high and stable protein production in mammalian cells, Nature Biotechnology, May 2003, pp. 553-558, Vol. 21, Nature Publishing Group, US	<input type="checkbox"/>
26	VICTOR LEVITSKY, ET AL., Nucleosomal DNA property database, Bioinformatics, 1999, pp. 582-592, Vol. 15, Nos. 7/8, Oxford University Press, UK	<input type="checkbox"/>
27	ROBERT MCKNIGHT, ET AL., Matrix-attachment regions can impart position-independent regulation of a tissue-specific gene in transgenic mice, Genetics, August 1992, pp. 6943-6947, Vol. 89, Proc. Natl. Acad. Sci. USA, US	<input type="checkbox"/>
28	SYLVIA MIESCHER, ET AL., CHO expression of a novel human recombinant IgG1 anti-RhD antibody isolated by phage display, British Journal of Haematology, 2000, pp. 157-166, Vol. 111, Blackwell Science Ltd., UK	<input type="checkbox"/>
29	GRANT MACGREGOR and C. THOMAS CASKEY, Construction of plasmids that express E. coli β -galactosidase in mammalian cells, Nucleic Acids Research, 1989, p. 2365, Vol. 17, No. 6, IRL Press, US	<input type="checkbox"/>
30	TOBIAS NEFF, ET AL., Stem Cell Gene Therapy, Position Effects and Chromatin Insulators, Hematopoietic Stem Cells, Stem Cells, 1997, pp. 265-271, Vol. 15(suppl 1), AlphaMed Press, US	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10595495
Filing Date		2006-04-24
First Named Inventor	Mermod et al.	
Art Unit		
Examiner Name		
Attorney Docket Number		3024-119

31	BEJAMIN ORTIZ, ET AL., Adjacent DNA elements dominantly restrict the ubiquitous activity of a novel chromatin-opening region to specific tissues, The EMBO Journal, 1997, pp. 5037-5045, Vol. 16, No. 16, Oxford University Press, UK	<input type="checkbox"/>
32	LOC PHI-VAN, ET AL., The Chicken Lysozyme 5' Matrix Attachment Region Increases Transcription from a Heterologous Promoter in Heterologous Cells and Dampens Position Effects on the Expression of Transfected Genes, Molecular and Cellular Biology, May 1990, pp. 2302-2307, Vol. 10, No. 5, American Society for Microbiology, US	<input type="checkbox"/>
33	C. PIECHACZEK, ET AL., A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells, Nucleic Acids Research, 1999, pp. 426-428, Vol. 27, No. 2, Oxford University Press, UK	<input type="checkbox"/>
34	LEONORA POLJAK, ET AL., SARs stimulate but do not confer position independent gene expression, Nucleic Acids Research, 1994, pp. 4386-4394, Vol. 22, No. 21, Oxford University Press, UK	<input type="checkbox"/>
35	PIERRE ROLLINI, ET AL. Identification and characterization of nuclear matrix-attachment regions in the human serpin gene cluster at 14q32.1, Nucleic Acids Research, 1999, pp. 3779-3791, Vol. 27, No. 19, Oxford University Press, UK	<input type="checkbox"/>
36	GAUTAM SINGH, ET AL., Mathematical model to predict regions of chromatin attachment to the nuclear matrix, Nucleic Acids Research, 1997, pp. 1419-1425, Vol. 25, No. 7, Oxford University Press, UK	<input type="checkbox"/>
37	T. D. SOUTHGATE, ET AL., Transcriptional Targeting to Anterior Pituitary Lactotrophic Cells Using Recombinant Adenovirus Vectors in Vitro and in Vivo in Normal and Estrogen/Sulpiride-Induced Hyperplasic Anterior Pituitaries, Endocrinology, 2000, pp. 3493-3505, Vol. 141, No. 9, The Endocrine Society, US	<input type="checkbox"/>
38	DALE TALBOT, ET AL., The 5' flanking region of the rat LAP (C/EBP β) gene can direct high-level, position-independent, copy numberdependent expression in multiple tissues in transgenic mice, Nucleic Acids Research, 1994, pp. 756-766, Vol. 22, No. 5, Oxford University Press, US	<input type="checkbox"/>
39	MASAAKI TATSUKA, ET AL., Experimental Cell Research, 1988, pp. 154-162, Vol. 178, Academic Press, Inc., SE	<input checked="" type="checkbox"/>
40	ANDOR UDVARY, Dividing the empire: boundary chromatin elements delimit the territory of enhancers, The EMBO Journal, 1999, pp. 1-8, Vol. 18, No. 1.	<input type="checkbox"/>
41	MARK WALTERS, ET AL., The Chicken b-Globin 59HS4 Boundary Element Blocks Enhancer-Mediated Suppression of Silencing, MARK WALTERS, ET AL., The Chicken b-Globin 59HS4 Boundary Element Blocks Enhancer-Mediated Suppression of Silencing, Molecular and Cellular Biology, May 1999, pp. 3714-3726, Vol. 19, No. 5, American Society for Microbiology, US Molecular and Cellular Biology, May 1999, pp. 3714-3726, Vol. 19, No. 5, American Society for Microbiology, US	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10595495
Filing Date	2006-04-24
First Named Inventor	Mermod et al.
Art Unit	
Examiner Name	
Attorney Docket Number	3024-119

42	YAOLIN WANG, ET AL., Ligand-inducible and liver-specific target gene expression in transgenic mice, Nature Biotechnology, March 1997, pp. 239-243, Vol. 15, Nature Publishing Group, US	<input type="checkbox"/>
43	KEVIN WELLS, ET AL., Codon optimization, genetic insulation, and an rtTA reporter improve performance of the tetracycline switch, Transgenic Research, 1999, pp. 371-381, Vol. 8, Kluwer Academic Publishers, NL	<input checked="" type="checkbox"/>
44	MONIQUE ZAHN-ZABAL, ET AL., Development of stable cell lines for production or regulated expression using matrix attachment regions, Journal of Biotechnology, 2001, pp. 29-42, Vol. 87, Elsevier Science Ltd., US	<input type="checkbox"/>
45	ROBERT PAWLIUK, ET AL., Retroviral vectors aimed at the gene therapy of human beta-globin gene disorder, Annals New York Academy of Sciences, 1998, pp. 151-162, Vol. 850, New York Academy of Sciences, US	<input type="checkbox"/>
46	MARTIN FUSSENEGGER, ET AL., Genetic optimization of recombinant glycoprotein production by mammalian cells, TIBTECH, January 1999, pp. 35-42, Vol. 17, Elsevier Science Ltd., US	<input type="checkbox"/>
47	N. M. GREENBERG, ET AL., The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice, Molecular Endocrinology, 1994, pp. 230-239, Vol. 8, No. 2, The Endocrine Society, US	<input type="checkbox"/>
48	CORNELIA M. GORMAN and BRUCE H. HOWARD, Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate, Nucleic Acids Research, 1983, pp. 7631-7648, Vol. 11, No. 21, IRL Press Limited, UK	<input type="checkbox"/>
49	MARKUS O. IMHOF, ET AL., A regulatory network for the efficient control of transgene expression, THE JOURNAL OF GENE MEDICINE, 2000, pp. 107-116, Vol. 2, John Wiley & Sons, Ltd., US	<input type="checkbox"/>
50	ARIBERT STIEF, ET AL. A nuclear DNA attachment element mediates elevated and position-independent gene activity, Nature, 28 September 1989, pp. 343-345, Vol. 341, Nature Publishing Group, US	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10595495
Filing Date	2006-04-24
First Named Inventor	Mermod et al.
Art Unit	
Examiner Name	
Attorney Docket Number	3024-119

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10595495
Filing Date	2006-04-24
First Named Inventor	Mermod et al.
Art Unit	
Examiner Name	
Attorney Docket Number	3024-119

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Joyce v. Natzmer/	Date (YYYY-MM-DD)	2007-01-30
Name/Print	Joyce von Natzmer	Registration Number	48120

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.